目的 探討康艾注射液聯(lián)合低分子肝素鈣治療老年慢性阻塞性肺疾病急性加重期的臨床療效。方法 選取2015年9月-2016年9月在興安盟人民醫(yī)院進行治療的老年慢性阻塞性肺疾病急性加重期患者92例，隨機分為對照組（46例）和治療組（46例）。對照組皮下注射低分子肝素鈣注射液，0.6 mL/次，2次/d。治療組在對照組的基礎(chǔ)上靜脈滴注康艾注射液，60 mL加入5%葡萄糖注射液250 mL中，1次/d。兩組患者均連續(xù)治療2周。觀察兩組臨床療效，同時比較兩組患者治療前后臨床癥狀評分、肺功能和動脈血氣指標以及血清P-選擇素和D-二聚體（DD）水平變化。結(jié)果 治療后，對照組和治療組的總有效率分別為80.43%和95.65%，兩組總有效率比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者咳嗽、咳痰及氣促評分均顯著降低（P<0.05）；且治療組上述臨床癥狀評分降低更明顯（P<0.05）。治療后，兩組患者第1秒時間肺活量（FEV₁）、用力肺活量（FVC）、最大呼氣流量（PEF）等肺功能和血氧分壓（pO₂）、二氧化碳分壓（pCO₂）動脈血氣指標水平均明顯降低（P<0.05）；且與對照組相比，治療后治療組降低的更明顯（P<0.05）。治療后，兩組患者血清P-選擇素和DD水平均明顯降低（P<0.05）；且與對照組相比，治療組降低更明顯（P<0.05）。結(jié)論 康艾注射液聯(lián)合低分子肝素鈣治療老年慢性阻塞性肺疾病急性加重期效果顯著，可明顯改善患者臨床癥狀及肺功能，具有一定的臨床應(yīng)用價值。

Objective To investigate the clinical efficacy of Kang'ai Injection combined with low molecular weight heparins calcium in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (92 cases) with acute exacerbation of chronic obstructive pulmonary disease in Neimenggu Xing'an League People's Hospital from September 2015 to September 2016 were randomly divided into the control (46 cases) and treatment (46 cases) groups. The patients in the control group were sc administered with Low Molecular Weight Heparins Calcium Injection, 0.6 mL/time, twice daily. The patients in the treatment group were iv administered with Kang'ai Injection on the basis of the control group, 60 mL added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of clinical symptom scores, pulmonary function and arterial blood gas indexes, serum levels of P-selectin and DD in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 80.43% and 95.65%, respectively, and there were differences between two groups (P<0.05). After treatment, cough, expectoration, and shortness of breath scores in two groups were significantly decreased (P<0.05). And these clinical symptom scores in treatment group were more significantly decreased than those in the control group (P<0.05). After treatment, FEV₁, FVC, PEF, pO₂, and pCO₂ in two groups were significantly decreased (P<0.05). And compared with the control group, these observation indexes in the treatment group were more obviously decreased than those in the control group (P<0.05). After treatment, P-selectin and DD levels in two groups were significantly decreased (P<0.05). And compared with the control group, these indicators in the treatment group were more significantly decreased than those in the control group (P<0.05). Conclusion Kang'ai Injection combined with low molecular weight heparins calcium has a significant clinical efficacy in treatment of acute exacerbation of chronic obstructive pulmonary disease, can significantly improve the clinical symptoms and pulmonary function, which has a certain clinical application value.